Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10382 in Chronic Myeloid Leukemia
NCT05367700Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TERN-701 in chronic myeloid leukemia (CML) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 35 days and Major Cytogenetic Response at 6 months. Started Apr 2022; status: recruiting.
02
Drugs
TERN-701
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05367700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367700.